Cargando…
PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431620/ http://dx.doi.org/10.1097/01.HS9.0000851276.20930.ad |
| _version_ | 1784780105609904128 |
|---|---|
| author | Nowakowski, G. S. Yoon, D. H. Joffe, E. Zinzani, P. L. Sabatelli, L. Waltl, E. E. Alvero, C. G. Hess, G. Riedell, P. Kim, K. Brixner, D. Salles, G. |
| author_facet | Nowakowski, G. S. Yoon, D. H. Joffe, E. Zinzani, P. L. Sabatelli, L. Waltl, E. E. Alvero, C. G. Hess, G. Riedell, P. Kim, K. Brixner, D. Salles, G. |
| author_sort | Nowakowski, G. S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431620 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94316202022-08-31 PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Nowakowski, G. S. Yoon, D. H. Joffe, E. Zinzani, P. L. Sabatelli, L. Waltl, E. E. Alvero, C. G. Hess, G. Riedell, P. Kim, K. Brixner, D. Salles, G. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431620/ http://dx.doi.org/10.1097/01.HS9.0000851276.20930.ad Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Nowakowski, G. S. Yoon, D. H. Joffe, E. Zinzani, P. L. Sabatelli, L. Waltl, E. E. Alvero, C. G. Hess, G. Riedell, P. Kim, K. Brixner, D. Salles, G. PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title | PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full | PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_fullStr | PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full_unstemmed | PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_short | PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
| title_sort | pb2111: subgroup analysis in re-mind2, an observational, retrospective cohort study of tafasitamab + lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large b-cell lymphoma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431620/ http://dx.doi.org/10.1097/01.HS9.0000851276.20930.ad |
| work_keys_str_mv | AT nowakowskigs pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT yoondh pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT joffee pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT zinzanipl pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sabatellil pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT waltlee pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT alverocg pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT hessg pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT riedellp pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT kimk pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT brixnerd pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma AT sallesg pb2111subgroupanalysisinremind2anobservationalretrospectivecohortstudyoftafasitamablenalidomideversussystemictherapiesinpatientswithrelapsedrefractorydiffuselargebcelllymphoma |